{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:24:22Z","timestamp":1790515462128,"version":"4.1.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009104","name":"DHR","doi-asserted-by":"publisher","award":["GIA\/59\/2014-DHR"],"award-info":[{"award-number":["GIA\/59\/2014-DHR"]}],"id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"SERB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001342","name":"DST","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"UGC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001332","name":"CSIR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejphar.2018.12.003","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T11:57:09Z","timestamp":1544183829000},"page":"231-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives"],"prefix":"10.1016","volume":"844","author":[{"given":"Raghunath","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-641X","authenticated-orcid":false,"given":"Bikash","family":"Medhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Kuhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.12.003_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.regpep.2007.10.006","article-title":"Brain circuits regulating energy homeostasis","volume":"149","author":"Abizaid","year":"2008","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejphar.2018.12.003_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0269881108089816","article-title":"Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial","volume":"23","author":"Afshar","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2018.12.003_bib4","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.003_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40272-013-0016-6","article-title":"Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis","volume":"15","author":"Almandil","year":"2013","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.ejphar.2018.12.003_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488610789869265","article-title":"QT alterations in psychopharmacology: proven candidates and suspects","volume":"5","author":"Alvarez","year":"2010","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ejphar.2018.12.003_bib7","first-page":"112","article-title":"A diet and fitness program similarly affects weight reduction in schizophrenia patients treated with typical or atypical medications","volume":"26","author":"Amiaz","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tins.2010.10.001","article-title":"The extra-hypothalamic actions of ghrelin on neuronal function","volume":"34","author":"Andrews","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib9","first-page":"1130","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents","volume":"29","author":"Arman","year":"2008","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.ejphar.2018.12.003_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1590\/S1516-44462006000400005","article-title":"Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine","volume":"28","author":"Assun\u00e7\u00e3o","year":"2006","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.ejphar.2018.12.003_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00406-012-0302-2","article-title":"Homocysteine and cognition in first-episode psychosis patients","volume":"262","author":"Ayesa-Arriola","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00787-016-0866-x","article-title":"The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study","volume":"26","author":"Baeza","year":"2017","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib13","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","article-title":"Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure","volume":"2","author":"Bahr","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2018.12.003_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bph.12639","article-title":"Orexin\/hypocretin role in reward: implications for opioid and other addictions","volume":"172","author":"Baimel","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib15","doi-asserted-by":"crossref","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.003_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3371\/CSRP.5.1.3","article-title":"Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine","volume":"5","author":"Ball","year":"2011","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.ejphar.2018.12.003_bib17","article-title":"Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: a 7-month follow-up study","author":"Bal\u00f5t\u0161ev","year":"2017","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/070674370605100310","article-title":"Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial","volume":"51","author":"Baptista","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0028-1085438","article-title":"Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial","volume":"42","author":"Baptista","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib21","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.euroneuro.2015.06.011","article-title":"Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis","volume":"25","author":"Bartoli","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib23","first-page":"45","article-title":"Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle","volume":"62","author":"Basile","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0000000000000022","article-title":"Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia","volume":"29","author":"Biedermann","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00213-010-2124-0","article-title":"AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents","volume":"215","author":"Black","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib26","doi-asserted-by":"crossref","first-page":"e013154","DOI":"10.1136\/bmjopen-2016-013154","article-title":"Statin prescribing for people with severe mental illnesses: a staggered cohort study of \u2018real-world\u2019impacts","volume":"7","author":"Blackburn","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejphar.2018.12.003_bib27","first-page":"5","article-title":"Dopamine and glucose, obesity, and reward deficiency syndrome","author":"Blum","year":"2014","journal-title":"Front. Psychol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic\u2010induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.ejphar.2018.12.003_bib29","first-page":"8","article-title":"Low-dose of bergamot-derived polyphenolic fraction (BPF) did not improve metabolic parameters in second generation antipsychotics-treated patients: results from a 60-days open-label study","author":"Bruno","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.npp.1300089","article-title":"Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients","volume":"28","author":"Bustillo","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1194\/jlr.M026948","article-title":"Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro","volume":"54","author":"Canfr\u00e1n-Duque","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2017.03.003","article-title":"Acute variations of cytokine levels after antipsychotic treatment in drug-na\u00efve subjects with a first-episode psychosis: a meta-analysis","author":"Capuzzi","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejphar.2018.12.003_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.psyneuen.2017.05.005","article-title":"Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia","volume":"82","author":"Castellani","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.psyneuen.2018.03.021","article-title":"Leptin\/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia","volume":"92","author":"Chen","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2014.12.012","article-title":"Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms","volume":"53","author":"Chien","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.12.003_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.physbeh.2008.11.011","article-title":"Risperidone alters food intake, core body temperature, and locomotor activity in mice","volume":"96","author":"Cope","year":"2009","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2018.12.003_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":"The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis","volume":"112","author":"Cota","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.12.003_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/ejcn.2013.253","article-title":"The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity","author":"Cuerda","year":"2014","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.ejphar.2018.12.003_bib40","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/tp.2013.83","article-title":"Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat","volume":"3","author":"Davey","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-004-2017-1","article-title":"The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?","volume":"178","author":"Davies","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2004.03.005","article-title":"Amantadine for weight gain associated with olanzapine treatment","volume":"15","author":"Deberdt","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jpsychires.2009.10.011","article-title":"Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia","volume":"44","author":"del Rosario Garc\u00eda-Miss","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib46","doi-asserted-by":"crossref","first-page":"15046","DOI":"10.1038\/npjschz.2015.46","article-title":"The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects","volume":"1","author":"Ellingrod","year":"2015","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.ejphar.2018.12.003_bib47","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002","article-title":"Differential activation of orexin neurons by antipsychotic drugs associated with weight gain","volume":"22","author":"Fadel","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/acps.12009","article-title":"Metabolic effects of adjunctive aripiprazole in clozapine\u2010treated patients with schizophrenia","volume":"127","author":"Fan","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejphar.2018.12.003_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-naive individuals with non-affective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib51","doi-asserted-by":"crossref","first-page":"R905","DOI":"10.1152\/ajpregu.00092.2002","article-title":"Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake","volume":"283","author":"Fetissov","year":"2002","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/15622975.2014.984631","article-title":"The role of genetic variation across IL-1\u03b2, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain","volume":"16","author":"Fonseka","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib53","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1210\/endo.137.9.8756584","article-title":"The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes","volume":"137","author":"Gettys","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2013.03.021","article-title":"The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"147","author":"Ghanizadeh","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib55","first-page":"8","article-title":"Commentary: a randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","author":"Goltz","year":"2017","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2014.11.008","article-title":"Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms","volume":"25","author":"Gon\u00e7alves","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1192\/bjp.153.2.208","article-title":"A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity","volume":"153","author":"Goodall","year":"1988","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/0269881105058380","article-title":"Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?","author":"Gough","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2017.01.029","article-title":"Altered reward anticipation: potential explanation for weight gain in schizophrenia?","author":"Grimm","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejphar.2018.12.003_bib61","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2018.12.003_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psyneuen.2014.01.018","article-title":"Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"42","author":"He","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/104012371702900205","article-title":"Minimizing weight gain for patients taking antipsychotic medications: the potential role for early use of metformin","volume":"29","author":"Hendrick","year":"2017","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.111.087213","article-title":"Energy balance and obesity","volume":"126","author":"Hill","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.12.003_bib65","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF00442551","article-title":"The history of clozapine","volume":"99","author":"Hippius","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib66","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/dom.12148","article-title":"Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5\u2032\u2010monophosphate\u2010activated protein kinase","volume":"15","author":"Ikegami","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2018.12.003_bib67","first-page":"4","article-title":"Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist\u2014protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol","author":"Ish\u00f8y","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejphar.2018.12.003_bib68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00213-011-2397-y","article-title":"Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat","volume":"219","author":"Jassim","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.v69n0503","article-title":"Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial","volume":"69","author":"Joffe","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00406-017-0820-z","article-title":"The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain","volume":"268","author":"Kanji","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41398-018-0116-8","article-title":"Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota","volume":"8","author":"Kao","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib72","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/YIC.0000000000000132","article-title":"Adjunctive \u03b1-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study","volume":"31","author":"Kim","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib74","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib75","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/ajp.137.8.900","article-title":"Tardive dyskinesia: review and update","volume":"137","author":"Klawans","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib76","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1176\/ajp.2006.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","volume":"163","author":"Klein","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.npep.2012.09.004","article-title":"Arcuate NPY neurons sense and integrate peripheral metabolic signals to control feeding","volume":"46","author":"Kohno","year":"2012","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ejphar.2018.12.003_bib78","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib79","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2710.2011.01255.x","article-title":"A systematic review of metformin to limit weight\u2010gain with atypical antipsychotics","volume":"36","author":"Lee","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejphar.2018.12.003_bib80","first-page":"1","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"10","author":"Lett","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.12.003_bib82","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/oby.20350","article-title":"Effects of risperidone on energy balance in female C57BL\/6J mice","volume":"21","author":"Li","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2018.12.003_bib83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2016.02.011","article-title":"Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications","volume":"106","author":"Lian","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2016.02.011","article-title":"Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications","volume":"106","author":"Lian","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.06.010","article-title":"Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways","volume":"48","author":"Lian","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib86","doi-asserted-by":"crossref","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.003_bib87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.psychres.2018.02.058","article-title":"Early prediction of olanzapine-induced weight gain for schizophrenia patients","volume":"263","author":"Lin","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib88","article-title":"Hyperglycemia associated with the use of atypical antipsychotics","author":"Lindenmayer","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib89","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cyto.2011.10.001","article-title":"Both adiponectin and interleukin-10 inhibit LPS-induced activation of the NF-\u03baB pathway in 3T3-L1 adipocytes","volume":"57","author":"Lira","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.ejphar.2018.12.003_bib90","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cmet.2014.02.008","article-title":"Circuits controlling energy balance and mood: inherently intertwined or just complicated intersections?","volume":"19","author":"Liu","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2018.12.003_bib91","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI93362","article-title":"The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C","volume":"127","author":"Lord","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.12.003_bib92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.bp.106.031716","article-title":"Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community","volume":"191","author":"Mackin","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib93","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.psychres.2012.05.036","article-title":"Altered immune function in unaffected first-degree biological relatives of schizophrenia patients","volume":"200","author":"Mart\u00ednez-Gras","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib94","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2003.09.010","article-title":"What's atypical about atypical antipsychotic drugs?","volume":"4","author":"Meltzer","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib95","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2217\/epi.13.22","article-title":"The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation","volume":"5","author":"Misiak","year":"2013","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejphar.2018.12.003_bib97","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.psychres.2016.01.077","article-title":"Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism","volume":"238","author":"Misiak","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2017.06.046","article-title":"A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain","author":"Mittal","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib99","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis","volume":"40","author":"Mizuno","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejphar.2018.12.003_bib100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.npep.2006.07.003","article-title":"Quetiapine lowers sympathetic and hyperthermic reactions due to cerebral injection of orexin A","volume":"40","author":"Monda","year":"2006","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ejphar.2018.12.003_bib101","doi-asserted-by":"crossref","first-page":"e115225","DOI":"10.1371\/journal.pone.0115225","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse","volume":"9","author":"Morgan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.003_bib102","doi-asserted-by":"crossref","DOI":"10.1089\/cap.2016.0046","article-title":"Melatonin for reducing weight gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled trial","author":"Mostafavi","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib103","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.psyneuen.2007.05.007","article-title":"Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats","volume":"32","author":"Murashita","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib104","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1248\/bpb.b15-00842","article-title":"Mechanism underlying induction of hyperglycemia in rats by single administration of olanzapine","volume":"39","author":"Nagata","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2018.12.003_bib105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35051587","article-title":"A role for ghrelin in the central regulation of feeding","volume":"409","author":"Nakazato","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2018.12.003_bib106","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2014.08.018","article-title":"Schizophrenia and the gut\u2013brain axis","volume":"56","author":"Nemani","year":"2015","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib107","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1189\/jlb.0905521","article-title":"Different effects of adiponectin isoforms in human monocytic cells","volume":"79","author":"Neumeier","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib108","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2012.847","article-title":"Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia","volume":"69","author":"Nielsen","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib109","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2015.2582","article-title":"Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment","volume":"73","author":"Nielsen","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cyto.2017.04.004","article-title":"Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: an in vitro study","volume":"94","author":"Obuchowicz","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.ejphar.2018.12.003_bib111","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.12.003_bib112","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1440-1681.2005.04184.x","article-title":"Resistance to excessive bodyweight gain in risperidone\u2010injected rats","volume":"32","author":"Ota","year":"2005","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib113","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000204100","article-title":"Induction of NPY\/AgRP orexigenic peptide expression in rat hypothalamus is an early event in fasting: relationship with circulating leptin, insulin and glucose","volume":"23","author":"Palou","year":"2009","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2018.12.003_bib114","first-page":"16","article-title":"Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies","volume":"2011","author":"Panariello","year":"2011","journal-title":"Schizophr. Res. Treat."},{"key":"10.1016\/j.ejphar.2018.12.003_bib115","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM198804283181701","article-title":"Body fat and the activity of the autonomic nervous system","volume":"318","author":"Peterson","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.12.003_bib116","first-page":"S26","article-title":"Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis","volume":"60","author":"Potvin","year":"2015","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib117","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-007-0731-1","article-title":"Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study","volume":"192","author":"Poyurovsky","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib118","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","article-title":"Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine\u2013betahistine combination","volume":"226","author":"Poyurovsky","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","article-title":"The effect of betahistine, a histamine H1 receptor agonist\/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"20","author":"Poyurovsky","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.euroneuro.2003.10.004","article-title":"The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study","volume":"14","author":"Poyurovsky","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib121","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2013pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.12.003_bib122","article-title":"Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia","author":"Rickels","year":"2017","journal-title":"Am. J. Physiol. Metab."},{"key":"10.1016\/j.ejphar.2018.12.003_bib123","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/cc10021","article-title":"Clinical review: adiponectin biology and its role in inflammation and critical illness","volume":"15","author":"Robinson","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2018.12.003_bib124","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2217\/pgs.13.220","article-title":"Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics","volume":"15","author":"Roffeei","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejphar.2018.12.003_bib125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.npep.2015.04.001","article-title":"Effect of short and long-term treatment with antipsychotics on orexigenic\/anorexigenic neuropeptides expression in the rat hypothalamus","volume":"51","author":"Rojczyk","year":"2015","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ejphar.2018.12.003_bib126","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2016.04.051","article-title":"Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics","volume":"174","author":"Sapra","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2018.12.003_bib127","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","article-title":"Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro","volume":"450","author":"S\u00e1rv\u00e1ri","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2018.12.003_bib128","first-page":"180","article-title":"Folic acid metabolism and mechanisms of neural tube defects","volume":"181","author":"Scott","year":"1994","journal-title":"Ciba Found. Symp."},{"key":"10.1016\/j.ejphar.2018.12.003_bib129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/13813455.2011.576681","article-title":"Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat","volume":"117","author":"Smith","year":"2011","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2018.12.003_bib130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clinbiochem.2017.02.003","article-title":"Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders","volume":"50","author":"Srisawasdi","year":"2017","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejphar.2018.12.003_bib131","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1017\/S1461145713001375","article-title":"Methylenetetrahydrofolate reductase (MTHFR) 677C\/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia","volume":"17","author":"Srisawat","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib132","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib133","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug\u2010induced weight gain","volume":"17","author":"Stefanidis","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2018.12.003_bib134","first-page":"24","article-title":"Study of effects of modafinil add-on therapy on excessive day time drowsiness and weight gain in patients on atypical antipsychotics","volume":"30","author":"Sudhakar","year":"2008","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.ejphar.2018.12.003_bib135","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40264-015-0298-4","article-title":"Atypical antipsychotics and the risk of hyperlipidemia: a sequence symmetry analysis","volume":"38","author":"Takeuchi","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2018.12.003_bib136","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2018.12.003_bib137","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0000000000000192","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept","volume":"34","author":"Tek","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib138","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":"A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia","volume":"35","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2018.12.003_bib139","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1098\/rstb.2006.1859","article-title":"Appetite and energy balance signals from adipocytes","volume":"361","author":"Trayhurn","year":"2006","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2796.2004.01426.x","article-title":"Adiponectin\u2013journey from an adipocyte secretory protein to biomarker of the metabolic syndrome","volume":"257","author":"Trujillo","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2018.12.003_bib141","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.ijo.0801678","article-title":"Acute effects of brain-derived neurotrophic factor on energy expenditure in obese diabetic mice","volume":"25","author":"Tsuchida","year":"2001","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2018.12.003_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nicl.2015.03.016","article-title":"Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity","volume":"8","author":"Val-Laillet","year":"2015","journal-title":"NeuroImage Clin."},{"key":"10.1016\/j.ejphar.2018.12.003_bib143","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ijo.2011.97","article-title":"The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature","volume":"36","author":"Van Der Zwaal","year":"2012","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2018.12.003_bib144","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/1060028016638861","article-title":"Prevalence of antidiabetic and ntilipidemic medications in children and adolescents treated with atypical antipsychotics in a virginia medicaid population","volume":"50","author":"Varghese","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2018.12.003_bib145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tics.2010.11.001","article-title":"Reward, dopamine and the control of food intake: implications for obesity","volume":"15","author":"Volkow","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.ejphar.2018.12.003_bib146","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.12.003_bib147","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain","volume":"7","author":"Weston-Green","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.003_bib148","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1017\/S1461145708008560","article-title":"The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain","volume":"11","author":"Weston-Green","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib149","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4088\/JCP.v63n0412","article-title":"Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment","volume":"63","author":"White","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.12.003_bib150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib151","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2018.12.003_bib152","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1017\/S1461145713001697","article-title":"Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"17","author":"Zhang","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.12.003_bib153","article-title":"Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials","author":"Zheng","year":"2018","journal-title":"Pharmacopsychiatry"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918307052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918307052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:24:21Z","timestamp":1757975061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918307052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":153,"alternative-id":["S0014299918307052"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.12.003","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}